Report
Valens Research

ACAD - Embedded Expectations Analysis - 2019 06 10

ACADIA Pharmaceuticals Inc. (ACAD:USA) currently trades near recent lows relative to UAFRS-based (Uniform) Assets, with a 3.2x Uniform P/B. At these levels, the market has somewhat bullish expectations for the firm, but management has concerns about new patient start growth, negative symptom study controls, and their schizophrenia programs.

Specifically, management may lack confidence in their ability to maintain specialty distribution segment performance, sustain NUPLAZID new patient start growth, and stimulate therapy interest and awareness. Furthermore, they may be concerned about their patient selection strategy, negative symptom study controls, and the number of patients treated with multiple antipsychotics. Also, management may be concerned about the potential of primavanserin and their schizophrenia programs.
Underlying
ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines focusing on central nervous system disorders. The company has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch